AU2009243875B2 - 3, 4 - substituted piperidine derivatives as renin inhibitors - Google Patents

3, 4 - substituted piperidine derivatives as renin inhibitors Download PDF

Info

Publication number
AU2009243875B2
AU2009243875B2 AU2009243875A AU2009243875A AU2009243875B2 AU 2009243875 B2 AU2009243875 B2 AU 2009243875B2 AU 2009243875 A AU2009243875 A AU 2009243875A AU 2009243875 A AU2009243875 A AU 2009243875A AU 2009243875 B2 AU2009243875 B2 AU 2009243875B2
Authority
AU
Australia
Prior art keywords
alkylene
optionally substituted
halogens
methyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009243875A
Other languages
English (en)
Other versions
AU2009243875A1 (en
Inventor
Nadine Bremeyer
Louis-Charles Campeau
Austin Chih-Yu Chen
Daniel Dube
Pierre-Andre Fournier
Erich L. Grimm
Patrick Lacombe
Sebastien Laliberte
Dwight Macdonald
D. Bruce Mackay
Daniel James Mckay
Jeremy Peter Scott
Tom Yao-Hsiang Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of AU2009243875A1 publication Critical patent/AU2009243875A1/en
Application granted granted Critical
Publication of AU2009243875B2 publication Critical patent/AU2009243875B2/en
Assigned to MERCK SHARP & DOHME LIMITED, MERCK CANADA INC. reassignment MERCK SHARP & DOHME LIMITED Request to Amend Deed and Register Assignors: MERCK FROSST CANADA LTD., MERCK SHARP & DOHME LIMITED
Assigned to ACTELION PHARMACEUTICALS LTD reassignment ACTELION PHARMACEUTICALS LTD Request for Assignment Assignors: MERCK CANADA INC., MERCK SHARP & DOHME LIMITED
Assigned to IDORSIA PHARMACEUTICALS LTD reassignment IDORSIA PHARMACEUTICALS LTD Request for Assignment Assignors: ACTELION PHARMACEUTICALS LTD
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AU2009243875A 2008-05-05 2009-05-04 3, 4 - substituted piperidine derivatives as renin inhibitors Ceased AU2009243875B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12652908P 2008-05-05 2008-05-05
US61/126,529 2008-05-05
US18830308P 2008-08-07 2008-08-07
US61/188,303 2008-08-07
PCT/CA2009/000611 WO2009135299A1 (en) 2008-05-05 2009-05-04 3, 4 - substituted piperidine derivatives as renin inhibitors

Publications (2)

Publication Number Publication Date
AU2009243875A1 AU2009243875A1 (en) 2009-11-12
AU2009243875B2 true AU2009243875B2 (en) 2011-12-01

Family

ID=41264366

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009243875A Ceased AU2009243875B2 (en) 2008-05-05 2009-05-04 3, 4 - substituted piperidine derivatives as renin inhibitors

Country Status (23)

Country Link
US (1) US8889714B2 (https=)
EP (1) EP2274295B1 (https=)
JP (3) JP4790871B2 (https=)
KR (2) KR101403311B1 (https=)
CN (1) CN102015682B (https=)
AU (1) AU2009243875B2 (https=)
BR (1) BRPI0912388A2 (https=)
CA (1) CA2722734C (https=)
CO (1) CO6311081A2 (https=)
CR (1) CR11809A (https=)
DO (1) DOP2010000329A (https=)
EA (1) EA020853B1 (https=)
ES (1) ES2548134T3 (https=)
IL (1) IL208467A (https=)
MA (1) MA32296B1 (https=)
MX (1) MX2010012067A (https=)
MY (1) MY152042A (https=)
NI (1) NI201000188A (https=)
NZ (1) NZ589019A (https=)
PL (1) PL2274295T3 (https=)
SG (1) SG192543A1 (https=)
SV (1) SV2010003723A (https=)
WO (1) WO2009135299A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
EP2376473A4 (en) * 2008-12-10 2012-05-02 Merck Canada Inc 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS
TWI562977B (en) * 2010-11-05 2016-12-21 Bayer Ip Gmbh Process for the preparation of substituted n-(benzyl)cyclopropanamines by imine hydrogenation
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
CN107602381B (zh) * 2017-09-11 2021-03-16 陕西莱特光电材料股份有限公司 一种萘甲酸酯类衍生物及其制备方法
CN108033876A (zh) * 2017-12-20 2018-05-15 江汉大学 一种5-溴-2-氯苯甲醛的制备方法
US12459934B2 (en) 2018-11-28 2025-11-04 Basf Se Pesticidal compounds
WO2021219513A1 (en) 2020-04-28 2021-11-04 Basf Se Pesticidal compounds

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
TR199800409T1 (xx) 1995-09-07 1998-05-21 F.Hoffmann-La Roche Ag Kalp ve b�brek yetersizli�inin tedavii�in yeni 4-(oksialkoksifenil)-3-oksi-piperidinler
US5994294A (en) 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
WO1998019672A1 (en) 1996-11-01 1998-05-14 Nitromed Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IT1292426B1 (it) 1997-06-27 1999-02-08 Nicox Sa Sali nitrati di ace-inibitori
AU9598601A (en) 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
CA2483241C (en) 2002-04-29 2011-05-31 Actelion Pharmaceuticals Ltd Novel diazabicyclononene derivatives
RU2005102002A (ru) 2002-06-27 2005-09-20 Актелион Фармасьютиклз Лтд. (Ch) Новые производные тетрагидропиридина
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
CN1780836A (zh) 2003-04-28 2006-05-31 埃科特莱茵药品有限公司 作为血管紧张肽原酶抑制剂的新型二氮杂双环壬烯和四氢吡啶衍生物
JP2007523845A (ja) 2003-04-29 2007-08-23 アクテリオン　ファマシューティカルズ　リミテッド 新規３，４−ジ置換１，２，３，６−テトラヒドロピリジン誘導体
KR20060008937A (ko) 2003-04-30 2006-01-27 액테리온 파마슈티칼 리미티드 레닌 억제제로서 3-위치에 헤테로원자를 갖는9-아자비사이클로[3.3.1]논-6-엔 유도체
KR20060006069A (ko) 2003-04-30 2006-01-18 액테리온 파마슈티칼 리미티드 아자비사이클로노넨 유도체
JP2006524657A (ja) 2003-04-30 2006-11-02 アクテリオン　ファマシューティカルズ　リミテッド 新規トロパン誘導体
EP1622564A2 (en) 2003-05-02 2006-02-08 Actelion Pharmaceuticals Ltd. Diazabicyclononene derivatives
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
CA2540543A1 (en) 2003-10-09 2005-05-06 Actelion Pharmaceuticals Ltd Tetrahydropyridine derivatives
WO2005040165A1 (en) 2003-10-13 2005-05-06 Actelion Pharmaceuticals Ltd Diazabicyclononene derivatives and their use as renin inhibitors
CA2540817A1 (en) 2003-10-23 2005-05-06 Olivier Bezencon Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors
AU2004295092A1 (en) 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd. Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain
AU2004295091A1 (en) 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd Diazabicyclononene derivatives and their use as renin inhibitors
AR053406A1 (es) 2004-07-09 2007-05-09 Speedel Experimenta Ag Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas
WO2006021399A2 (en) 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Azabicyclononene derivatives as renin inhibitors
WO2006021401A2 (en) 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Bicylononene derivatives
ATE462703T1 (de) 2004-08-25 2010-04-15 Actelion Pharmaceuticals Ltd Bicyclononen-derivate als renin-inhibitoren
WO2006021403A1 (en) 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Bicyclononene derivatives
WO2006058546A1 (en) 2004-12-01 2006-06-08 Actelion Pharmaceuticals Ltd Novel lactame derivatives as renin inhibitors
AR052263A1 (es) 2004-12-08 2007-03-07 Actelion Pharmaceuticals Ltd Derivado de diazabiciclononeno
WO2006063610A1 (en) 2004-12-17 2006-06-22 Actelion Pharmaceuticals Ltd Heteroaryl substituted diazabicyclononene derivatives
GB0428526D0 (en) * 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0500784D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
KR100938364B1 (ko) 2005-01-28 2010-01-22 액테리온 파마슈티칼 리미티드 고혈압 치료를 위한, 레닌의 억제제로서의 7-｛4-[2-(2,6-디클로로-4-메틸페녹시)에톡시]페닐｝-3,9-디아자비시클로[3.3.1]논-6-엔-6-카르복실산 시클로프로필-(2,3-디메틸벤질)아미드
WO2006092268A1 (en) 2005-03-02 2006-09-08 Actelion Pharmaceuticals Ltd Bicyclic five-membered heteroaryl derivatives and their use as renin inhibitors
GB0504850D0 (en) 2005-03-09 2005-04-13 Novartis Ag Organic compounds
BRPI0609534A2 (pt) 2005-03-31 2010-04-13 Speedel Experimenta Ag piperidinas 3,4,5-substituìdas
TW200716622A (en) 2005-03-31 2007-05-01 Speedel Experimenta Ag Substituted piperidines
GB0510810D0 (en) * 2005-05-26 2005-06-29 Novartis Ag Organic compounds
GEP20115206B (en) * 2005-05-27 2011-04-26 Actelion Pharmaceuticals Ltd Novel piperidine carboxylic acid amide derivatives
GB0511063D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
WO2006131884A2 (en) 2005-06-07 2006-12-14 Actelion Pharmaceuticals Ltd Thiazole substituted diazabicyclononane or-nonene derivatives as renin inhibitors
JP2009502751A (ja) 2005-07-22 2009-01-29 メルク フロスト カナダ リミテツド レニン阻害薬
WO2007034406A1 (en) 2005-09-22 2007-03-29 Actelion Pharmaceuticals Ltd Pyrrolidine-3-carboxylic acid amide derivatives and their use as inhibitors of renin
WO2007034445A2 (en) 2005-09-26 2007-03-29 Actelion Pharmaceuticals Ltd Novel piperazine derivatives as renin inhibitors for cardiovascular events and renal insufficiency
WO2007049224A1 (en) 2005-10-25 2007-05-03 Actelion Pharmaceuticals Ltd Novel hexahydro- or octahydro-cyclopenta[c]pyrrole derivatives
BRPI0620736A2 (pt) 2005-12-30 2011-12-20 Novartis Ag compostos orgánicos
EP1816122A3 (en) 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
NZ570828A (en) 2006-02-02 2011-07-29 Actelion Pharmaceuticals Ltd Secondary amines as renin inhibitors
EP2029542A2 (en) 2006-03-03 2009-03-04 Actelion Pharmaceuticals Ltd. Primary amines as renin inhibitors
CN101395149A (zh) 2006-03-08 2009-03-25 埃科特莱茵药品有限公司 新颖胺类
US20090318501A1 (en) 2006-09-18 2009-12-24 Baldwin John J Piperidine derivatives as renin inhibitors
CA2668742A1 (en) * 2006-11-17 2008-05-22 Merck Frosst Canada Ltd. Renin inhibitors
AU2008253519A1 (en) * 2007-05-24 2008-11-27 Merck Frosst Canada Ltd Novel case of renin inhibitors
JP2010535716A (ja) 2007-08-07 2010-11-25 メルク フロスト カナダ リミテツド レニン阻害剤
US20100249163A1 (en) * 2007-12-04 2010-09-30 Daniel Dube Renin inhibitors
JP2011520924A (ja) 2008-05-22 2011-07-21 メルク フロスト カナダ リミテツド レニン阻害剤としての３，４−置換ピペリジン誘導体
US20120190701A1 (en) 2009-08-18 2012-07-26 Merck Sharp & Dohme Corp. Renin inhibitors

Also Published As

Publication number Publication date
PL2274295T3 (pl) 2016-01-29
CN102015682A (zh) 2011-04-13
MX2010012067A (es) 2010-12-06
KR101403311B1 (ko) 2014-06-05
MY152042A (en) 2014-08-15
KR20130029116A (ko) 2013-03-21
US8889714B2 (en) 2014-11-18
NZ589019A (en) 2012-10-26
US20110053940A1 (en) 2011-03-03
DOP2010000329A (es) 2011-01-15
CR11809A (es) 2011-01-10
ES2548134T3 (es) 2015-10-14
CA2722734A1 (en) 2009-11-12
CN102015682B (zh) 2014-07-16
SG192543A1 (en) 2013-08-30
EA201071269A1 (ru) 2011-06-30
JP2011519871A (ja) 2011-07-14
JP2011225579A (ja) 2011-11-10
MA32296B1 (fr) 2011-05-02
BRPI0912388A2 (pt) 2017-09-26
JP2011225580A (ja) 2011-11-10
NI201000188A (es) 2012-02-02
IL208467A (en) 2014-07-31
WO2009135299A1 (en) 2009-11-12
SV2010003723A (es) 2011-01-24
IL208467A0 (en) 2010-12-30
AU2009243875A1 (en) 2009-11-12
EA020853B1 (ru) 2015-02-27
EP2274295A1 (en) 2011-01-19
CA2722734C (en) 2013-11-05
CO6311081A2 (es) 2011-08-22
JP4790871B2 (ja) 2011-10-12
EP2274295A4 (en) 2012-03-28
JP5587246B2 (ja) 2014-09-10
KR20100131007A (ko) 2010-12-14
JP5653842B2 (ja) 2015-01-14
EP2274295B1 (en) 2015-08-05

Similar Documents

Publication Publication Date Title
AU2009243875B2 (en) 3, 4 - substituted piperidine derivatives as renin inhibitors
CN101910150B (zh) 作为cetp抑制剂、可用于治疗疾病如高脂血症或动脉硬化的4-苄基氨基-1-羧基酰基哌啶衍生物
AU2009250299A1 (en) 3, 4 - substituted piperidine derivatives as renin inhibitors
AU2009247262A1 (en) Amide compound
AU2003276201A1 (en) Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
CN106243037A (zh) 作为香草类化合物受体之配体的取代的苯基脲及苯基酰胺
AU2009326797B2 (en) 3,4 - substituted piperidine derivatives as renin inhibitors
TW202304864A (zh) 1,3-取代的環丁基衍生物及其用途
CA2347506C (en) Quinazolinone derivatives
TW201713622A (zh) 含氮雜環化合物
US10335402B2 (en) Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders
TWI472524B (zh) 腎素抑制劑
EA029430B1 (ru) Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ACTELION PHARMACEUTICALS LTD

Free format text: FORMER OWNER WAS: MERCK CANADA INC.; MERCK SHARP & DOHME LIMITED

PC Assignment registered

Owner name: IDORSIA PHARMACEUTICALS LTD

Free format text: FORMER OWNER(S): ACTELION PHARMACEUTICALS LTD

MK14 Patent ceased section 143(a) (annual fees not paid) or expired